Literature DB >> 33557283

Potential Role of Melatonin as an Adjuvant for Atherosclerotic Carotid Arterial Stenosis.

Rui Zhang1, Leng Ni1, Xiao Di1, Baitao Ma1, Shuai Niu1, Zhihua Rong1, Changwei Liu1.   

Abstract

Carotid artery stenosis (CAS) is an atherosclerotic disease characterized by a narrowing of the artery lumen and a high risk of ischemic stroke. Risk factors of atherosclerosis, including smoking, hypertension, hyperglycemia, hyperlipidemia, aging, and disrupted circadian rhythm, may potentiate atherosclerosis in the carotid artery and further reduce the arterial lumen. Ischemic stroke due to severe CAS and cerebral ischemic/reperfusion (I/R) injury after the revascularization of CAS also adversely affect clinical outcomes. Melatonin is a pluripotent agent with potent anti-inflammatory, anti-oxidative, and neuroprotective properties. Although there is a shortage of direct clinical evidence demonstrating the benefits of melatonin in CAS patients, previous studies have shown that melatonin may be beneficial for patients with CAS in terms of reducing endothelial damage, stabilizing arterial plaque, mitigating the harm from CAS-related ischemic stroke and cerebral I/R injury, and alleviating the adverse effects of the related risk factors. Additional pre-clinical and clinical are required to confirm this speculation.

Entities:  

Keywords:  atherosclerosis; carotid artery stenosis; ischemic stroke; melatonin

Mesh:

Substances:

Year:  2021        PMID: 33557283      PMCID: PMC7914857          DOI: 10.3390/molecules26040811

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  161 in total

Review 1.  Melatonin and circadian biology in human cardiovascular disease.

Authors:  Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Juan J Sanchez-Sanchez; Juan C Kaski; Russel J Reiter
Journal:  J Pineal Res       Date:  2010-06-01       Impact factor: 13.007

2.  The potential usefulness of serum melatonin level to predict heart failure in patients with hypertensive cardiomyopathy.

Authors:  Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez; Russel J Reiter
Journal:  Int J Cardiol       Date:  2014-04-15       Impact factor: 4.164

3.  Effects of melatonin on genetic hypercholesterolemia in rats.

Authors:  H Aoyama; N Mori; W Mori
Journal:  Atherosclerosis       Date:  1988-02       Impact factor: 5.162

4.  FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis.

Authors:  Zhaolin Zeng; Qiuping Zheng; Jiaojiao Chen; Xianhua Tan; Qiang Li; Lingxin Ding; Ren Zhang; Xiaolong Lin
Journal:  Exp Cell Res       Date:  2020-05-20       Impact factor: 3.905

5.  Advanced atherosclerosis is associated with inflammation, vascular dysfunction and oxidative stress, but not hypertension.

Authors:  Quynh N Dinh; Sophocles Chrissobolis; Henry Diep; Christopher T Chan; Dorota Ferens; Grant R Drummond; Christopher G Sobey
Journal:  Pharmacol Res       Date:  2016-12-23       Impact factor: 7.658

Review 6.  HDL and Reverse Cholesterol Transport.

Authors:  Mireille Ouimet; Tessa J Barrett; Edward A Fisher
Journal:  Circ Res       Date:  2019-05-10       Impact factor: 17.367

Review 7.  Mitochondrial bioenergetics and redox dysfunctions in hypercholesterolemia and atherosclerosis.

Authors:  Helena C F Oliveira; Anibal E Vercesi
Journal:  Mol Aspects Med       Date:  2019-12-25

8.  Melatonin Inhibits in Vitro Smooth Muscle Cell Inflammation and Proliferation and Atherosclerosis in Apolipoprotein E-Deficient Mice.

Authors:  Hung-Yuan Li; Yann-Lii Leu; Ya-Chieh Wu; Shu-Huei Wang
Journal:  J Agric Food Chem       Date:  2019-02-05       Impact factor: 5.279

Review 9.  Mitochondria: Central Organelles for Melatonin's Antioxidant and Anti-Aging Actions.

Authors:  Russel J Reiter; Dun Xian Tan; Sergio Rosales-Corral; Annia Galano; Xin Jia Zhou; Bing Xu
Journal:  Molecules       Date:  2018-02-24       Impact factor: 4.411

10.  Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition.

Authors:  Sai Ma; Jiangwei Chen; Jing Feng; Ran Zhang; Miaomiao Fan; Dong Han; Xiang Li; Congye Li; Jun Ren; Yabin Wang; Feng Cao
Journal:  Oxid Med Cell Longev       Date:  2018-09-04       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.